文献速递头颈部肿瘤放疗中枢神经肿瘤放疗

头颈癌调强放疗后Lhermitte征危险因素的识别

Identifying risk factors for L'Hermitte's sign after IMRT for head and neck cancer.
PubMed 文献 · Radiat Oncol · 2018-05-04

117例2008至2015年接受螺旋断层放疗的头颈癌患者前瞻性完成副作用问卷,42例(35.9%)报告Lhermitte征。同步每周顺铂未增加风险(p=0.70),糖尿病患者发生率更低(p=0.025),单侧放疗者风险更高(p=0.019),较高V40Gy与较年轻年龄呈边缘显著关联。

要点

  • 117例头颈癌患者调强放疗后Lhermitte征发生率为35.9%(42例)。
  • 同步每周顺铂未增加Lhermitte征风险(p=0.70,OR=1.23,95%CI 0.51-2.34)。
  • 单侧放疗者更易发生Lhermitte征(p=0.019,OR=2.06,95%CI 0.15-0.84)。

核心结论

  • 在本队列中,同步顺铂未增加Lhermitte征风险,糖尿病患者Lhermitte征发生率较低。
  • 患者年龄和脊髓剂量梯度可能是重要因素。

研究设计与样本

  • 2008年至2015年接受TomoTherapy™治疗的117例头颈癌患者前瞻性完成副作用问卷(VoxTox试验注册号:UK CRN ID 13716)。
  • 收集基线患者和治疗数据,分析放疗计划中脊髓平均剂量、最大剂量及接受10、20、30和40 Gy的体积,并检查脊髓剂量变化,纳入逻辑回归模型。

主要发现

  • 42例患者(35.9%)报告Lhermitte征症状。
  • 同步每周顺铂未增加Lhermitte征风险(p=0.70,OR=1.23,95%CI 0.51-2.34)。
  • 13例糖尿病患者(9例服用二甲双胍)中仅1例发生Lhermitte征(p=0.025,OR=0.13,95%CI 0.051-3.27)。
  • 精细二元逻辑回归模型显示,接受单侧放疗的患者更可能发生Lhermitte征(p=0.019,OR=2.06,95%CI 0.15-0.84)。
  • 较高V40Gy(p=0.047,OR=1.06,95%CI 1.00-1.12)和较年轻年龄(平均年龄56.6 vs 59.7,p=0.060,OR=0.96,95%CI 0.92-1.00)与Lhermitte征风险升高相关,呈边缘显著性。

关键数值与推荐

  • Lhermitte征症状报告率为35.9%(42/117)。
  • 同步每周顺铂:p=0.70,OR=1.23(95%CI 0.51-2.34)。
  • 糖尿病:p=0.025,OR=0.13(95%CI 0.051-3.27)。
  • 单侧放疗:p=0.019,OR=2.06(95%CI 0.15-0.84)。
  • V40Gy:p=0.047,OR=1.06(95%CI 1.00-1.12);年龄:平均56.6 vs 59.7,p=0.060,OR=0.96(95%CI 0.92-1.00)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: L'Hermitte's sign (LS) after chemoradiotherapy for head and neck cancer appears related to higher spinal cord doses. IMRT plans limit spinal cord dose, but the incidence of LS remains high. METHODS: One hundred seventeen patients treated with TomoTherapy™ between 2008 and 2015 prospectively completed a side-effect questionnaire (VoxTox Trial Registration: UK CRN ID 13716). Baseline patient and treatment data were collected. Radiotherapy plans were analysed; mean and maximum spinal cord dose and volumes receiving 10, 20, 30 and 40 Gy were recorded. Dose variation across the cord was examined. These data were included in a logistic regression model. RESULTS: Forty two patients (35.9%) reported LS symptoms. Concurrent weekly cisplatin did not increase LS risk (p = 0.70, OR = 1.23 {95% CI 0.51-2.34}). Of 13 diabetic participants (9 taking metformin), only 1 developed LS (p = 0.025, OR = 0.13 {95% CI 0.051-3.27}). A refined binary logistic regression model showed that patients receiving unilateral radiation (p = 0.019, OR = 2.06 {95% CI 0.15-0.84}) were more likely to develop LS. Higher V40Gy (p = 0.047, OR = 1.06 {95% CI 1.00-1.12}), and younger age (mean age 56.6 vs 59.7, p = 0.060, OR = 0.96 {95% CI 0.92-1.00}) were associated with elevated risk of LS, with borderline significance. CONCLUSIONS: In this cohort, concomitant cisplatin did not increase risk, and LS incidence was lower in diabetic patients. Patient age and dose gradients across the spinal cord may be important factors.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Laidley HM, Noble DJ, Barnett GC, et al. Identifying risk factors for L'Hermitte's sign after IMRT for head and neck cancer. Radiat Oncol. 2018. PMID: 29728105. doi:10.1186/s13014-018-1015-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。